Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesMulticenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
Journal of Clinical Oncology, 05/21/09
George S et al. - In a study to evaluate the potential benefit of continuous daily dosing sunitinib in pts with advanced nongastrointestinal stromal tumor (GIST) sarcomas, sunitinib demonstrated notable evidence of metabolic response in several pts with non-GIST sarcoma. The relevance of disease control observed in subtypes with an indolent natural history is unknown, however, the durable disease control observed in DSRCT, solitary fibrous tumor, and giant cell tumor of bone suggests that future evaluation of sunitinib in these subtypes may be warranted.
Methods- 53 pts with advanced non-GIST soft tissue sarcomas received sunitinib 37.5 mg daily.
- Primary endpoint was Response Evaluation Criteria in Solid Tumors defined response.
- Secondary endpoints were stable disease at 16 and 24 wks.
- [18F]-fluorodeoxyglucose positron emission tomography was performed on a subset of 24 pts at baseline and after 10 to 14 days of therapy.
- 48 pts were eligible for response.
- 1 pt (desmoplastic round cell tumor [DSRCT]) achieved a confirmed partial response (PR) and remained on study for 56 wks.
- 10 pts (20%) achieved stable disease for at least 16 wks.
- Metabolic PR was seen in 10 (47%) of 21 of pts.
- Metabolic stable disease was seen in 11 (52%) of 21.
- There were no unexpected toxicities observed.
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Is there a role for intensifying induction therapy in acute myeloid leukaemia (AML)?
Best Practice & Research: Clinical Haematology , 12/08/09
Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias
Haematologica, 12/08/09
New agents for AML and MDS
Best Practice & Research: Clinical Haematology , 12/08/09
Today in Soft Tissue/Sarcoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Angiosarcoma of the Breast: A Rare Clinicopathological Entity
American Journal of Clinical Oncology, 12/08/09
Interaction of Histologic Subtype and Histologic Grade in Predicting Survival for Soft-Tissue Sarcomas
Journal of the American College of Surgeons, 12/08/09
Surgical treatment of pelvic chondrosarcoma involving periacetabulum
Journal of Surgical Oncology, 12/08/09
Sponsor
Article Search
Sponsor
Sponsor